SEC Form 4 · accession 0000920465-18-000066
LA JOLLA PHARMACEUTICAL CO · LJPC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
James Rolke
Officer — Chief Scientific Officer
Period of report
Dec 14, 2018
Accepted (ET)
Dec 17, 2018 · 8:28 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000920465
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Dec 14, 2018 | A | 70 | $10.88 | A | 74,633 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $12.80 | Dec 14, 2018 | A | 70 | A | — | Dec 14, 2028 | Common Stock | 70 | 70 | D |
Explanation of responses
- F1These shares were acquired on 12/14/2018 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).
- F2The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years.